当前位置: 首页 >> 检索结果
3624. Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State.
作者: Nicole Hua.;Alvaro Gomez.;Julius Lindblom.;Sharzad Emamikia.;Yvonne Enman.;David Grannas.;Emelie Heintz.;Malin Regardt.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2023年62卷12期3916-3923页
To investigate the ability of different EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) index scores to discriminate between verum drug and placebo (discriminant validity) as well as between responders and non-responders (known-groups validity) in the SLE patient population of two phase III clinical trials of belimumab.
3625. Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study.
作者: Takahiro Nishino.;Atsushi Hashimoto.;Shigeto Tohma.;Toshihiro Matsui.
来源: BMC Rheumatol. 2023年7卷1期4页
The effects and their magnitudes of sex on disease activity indices for rheumatoid arthritis are not clear. We aimed to comprehensively evaluate the influence of sex on disease activity indices in the real-world setting using a large observational database.
3626. Factors impacting women's advancement to positions on editorial boards of rheumatology journals.
作者: Jessica Day.;Pavel Ovseiko.;Tayyeba Khursheed.;Renil Titus.;Vikas Agarwal.;Laura Coates.;Latika Gupta.
来源: Rheumatology (Oxford). 2023年62卷9期e260-e262页 3627. Metabolic and inflammatory profiles define phenotypes with clinical relevance in female knee osteoarthritis patients with joint effusion.
作者: Joan Calvet.;María García-Manrique.;Antoni Berenguer-Llergo.;Cristóbal Orellana.;Silvia Garcia Cirera.;Maria Llop.;Carlos Galisteo Lencastre.;Marta Arévalo.;Cristina Aymerich.;Rafael Gómez.;Néstor Albiñana Giménez.;Jordi Gratacós.
来源: Rheumatology (Oxford). 2023年62卷12期3875-3885页
Osteoarthritis has been the subject of abundant research in the last years with limited translation to the clinical practice, probably due to the disease's high heterogeneity. In this study, we aimed to identify different phenotypes in knee osteoarthritis (KOA) patients with joint effusion based on their metabolic and inflammatory profiles.
3628. N-glycan in the variable region of monoclonal ACPA (CCP-Ab1) promotes the exacerbation of experimental arthritis.
作者: Masatoshi Kawataka.;Kazuhisa Ouhara.;Eiji Kobayashi.;Koichiro Shinoda.;Kazuyuki Tobe.;Ryousuke Fujimori.;Noriyoshi Mizuno.;Eiji Sugiyama.;Tatsuhiko Ozawa.;Hiroyuki Kishi.
来源: Rheumatology (Oxford). 2023年62卷12期3968-3977页
The variable region of most ACPA IgG molecules in the serum of RA patients carries N-glycan (N-glycanV). To analyse the pathogenicity of N-glycanV of ACPAs, we analysed the pathogenicity of a monoclonal ACPA, CCP-Ab1, with or without N-glycanV, which had been isolated from a patient with RA.
3629. Focal facial myositis-a paraneoplastic syndrome?
作者: Tiago Miguel Brandão de Melo Beirão.;Beatriz Samões.;Diogo Fonseca.;Catarina Rua.;Flávio Costa.;Romana Vieira.;Joana Aleixo.;Taciana Videira.;Cristina Ferreira.;Henrique Coelho.;Patrícia Pinto.
来源: Rheumatology (Oxford). 2023年62卷10期e297-e298页 3631. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
作者: Lianne Kearsley-Fleet.;Aasiyah Rokad.;Man-Fung Tsoi.;Sizheng Steven Zhao.;Mark Lunt.;Kath D Watson.; .;Kimme L Hyrich.
来源: Rheumatology (Oxford). 2023年62卷12期3849-3857页
Etanercept biosimilars show comparable efficacy to their originators among biologic-naïve patients with RA in randomized controlled trials. Nationwide guidelines have obligated prescribing of etanercept biosimilars from 2016, resulting in significant cost savings. This analysis aimed to compare the effectiveness of etanercept originator vs etanercept biosimilar amongst biologic-naïve RA patients treated in routine clinical practice in the UK.
3632. Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.
作者: Till Uhlig.;Lars F Karoliussen.;Joe Sexton.;Sella Aarrestad Provan.;Tore K Kvien.;Espen A Haavardsholm.;Hilde Berner Hammer.
来源: Rheumatology (Oxford). 2023年62卷12期3886-3892页
In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2 years.
3633. E-learning and practical performance in musculoskeletal ultrasound: a multicentre randomized study.
作者: Stine Maya Dreier Carstensen.;Søren Andreas Just.;Marie Velander.;Lars Konge.;Martin Slusarczyk Hubel.;Thiusius Rajeeth Savarimuthu.;Mogens Pfeiffer Jensen.;Mikkel Østergaard.;Lene Terslev.
来源: Rheumatology (Oxford). 2023年62卷11期3547-3554页
To examine the effect of pre-course e-learning on residents' practical performance in musculoskeletal ultrasound (MSUS).
3634. Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes.
作者: Akira Onishi.;Hideaki Tsuji.;Yudai Takase.;Yuto Nakakubo.;Takeshi Iwasaki.;Tomohiro Kozuki.;Tsuneyasu Yoshida.;Mirei Shirakashi.;Hideo Onizawa.;Ryosuke Hiwa.;Koji Kitagori.;Shuji Akizuki.;Ran Nakashima.;Hajime Yoshifuji.;Masao Tanaka.;Akio Morinobu.
来源: Rheumatology (Oxford). 2023年62卷12期3909-3915页
Although the SLE Disease Activity Score (SLE-DAS) and its definitions to classify disease activity have been recently developed to overcome the drawbacks of the SLE Disease Activity Index 2000 (SLEDAI-2K), the performance of the SLE-DAS for patient-reported outcomes (PROs) has not been fully examined. We aimed to compare SLE-DAS with SLEDAI-2K and validate the classifications of disease activity based on SLE-DAS in terms of PROs.
3635. Comment on: Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.
作者: Jacopo Ciaffi.;Sophie I E Liem.;Nina M van Leeuwen.;Cornelia F Allaart.;Tom W J Huizinga.;Jeska K de Vries-Bouwstra.
来源: Rheumatology (Oxford). 2023年62卷8期e251-e253页 3637. Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications.
作者: Jina Yeo.;Soon Ho Yoon.;Ju Yeon Kim.;Jeong Seok Lee.;Eun Young Lee.;Jin Mo Goo.;Lila Pourzand.;Jonathan G Goldin.;Grace-Hyun J Kim.;You-Jung Ha.
来源: Rheumatology (Oxford). 2023年62卷11期3690-3699页
To investigate computer-aided quantitative scores from high-resolution CT (HRCT) images and determine their longitudinal changes and clinical significance in patients with idiopathic inflammatory myopathies (IIMs)-related interstitial lung disease (IIMs-ILD).
3638. Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.
作者: Didem Saygin.;Hanna Kim.;Christian Douglas.;Brian Erman.;Jesse Wilkerson.;John A McGrath.;Chester V Oddis.;Ingrid E Lundberg.;Anthony A Amato.;Ignacio García-De La Torre.;Hector Chinoy.;David Fiorentino.;Lorinda Chung.;Yeong-Wook Song.;Frederick W Miller.;Nicolino Ruperto.;Jiri Vencovsky.;Rohit Aggarwal.;Lisa G Rider.; .
来源: Rheumatology (Oxford). 2023年62卷11期3672-3679页
The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening.
3639. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.
作者: Hanna Kim.;Didem Saygin.;Christian Douglas.;Jesse Wilkerson.;Brian Erman.;Angela Pistorio.;John A McGrath.;Ann M Reed.;Chester V Oddis.;Claudia Bracaglia.;Annet van Royen-Kerkhof.;Blanca Bica.;Pavla Dolezalova.;Virginia P L Ferriani.;Berit Flato.;Ana G Bernard-Medina.;Troels Herlin.;Frederick W Miller.;Jiri Vencovsky.;Nicolino Ruperto.;Rohit Aggarwal.;Lisa G Rider.; .
来源: Rheumatology (Oxford). 2023年62卷11期3680-3689页
The 2016 ACR-EULAR Response Criteria for JDM was developed as a composite measure with differential weights of six core set measures (CSMs) to calculate a Total Improvement Score (TIS). We assessed the contribution of each CSM, representation of muscle-related and patient-reported CSMs towards improvement, and frequency of CSM worsening across myositis response criteria (MRC) categories in validation of MRC.
3640. Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus.
作者: Filippo Fagni.;Alessandra Bettiol.;Elena Silvestri.;Roberto Fedi.;Adalgisa Palermo.;Maria Letizia Urban.;Ruggero Mazzotta.;Danilo Malandrino.;Federica Bello.;Irene Mattioli.;David Simon.;Gerardo Di Scala.;Georg Schett.;Domenico Prisco.;Giacomo Emmi.
来源: Rheumatology (Oxford). 2023年62卷11期3619-3626页
To assess the prevalence of US-confirmed enthesitis in a cohort of patients with SLE and to analyse the clinical associations to enthesitis during the course of SLE.
|